A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

Prior treatment

• Participant should have no reason to not take a TNF inhibitor.
• Participants must not have had a live vaccine within four weeks of study start.

Other illness

• Participants must not have cancer.
• Participants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness.
• Participants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year.

Other

• Participants must not be pregnant or breastfeeding.
• Participants must not have had more than one VTE.
• Participants must not have participated in any other clinical trial within four weeks of study start.

• Participants must have at least one of the following characteristics:
  • Documented evidence of a VTE prior to this study
  • At least 60 years of age
  • A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m²), or
  • Age 50 to less than 60 years and BMI 25 to less than 30 kg/m².
• Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drug (DMARD) (synthetic or biologic).